We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law. WARNER CHILCOTT PUBLIC LIMITED COMPANY2011 Full Year Financial Guidance(In millions of U.S. dollars, except per share amounts)Prior Guidance
February 2011 Current Guidance
March 2011Total Revenue (1)$2,700 to $2,800$2,700 to $2,800Gross Margin as a % of Total Revenue (2)88% to 89%88% to 89%Total SG&A Expense (3)$900 to $950$900 to $950Total R&D Expense (4)$150 to $170$150 to $170Total Income Tax Provision (5)10%-11% of EBTA10%-11% of EBTAGAAP Net Income (6)$270 to $296$255 to $281Cash Net Income ("CNI") (7)$883 to $909$922 to $948CNI per share (6) (7)$3.45 to $3.55$3.60 to $3.70(1)
The 2011 guidance assumes (i) that generic equivalents of our DORYX 150 mg, ASACOL 400 mg and ESTRACE CREAM products will not be approved and enter the U.S. market during 2011; (ii) that a generic equivalent of FEMCON FE will be approved and enter the market as early as March 2011; (iii) the expected impact of the loss of exclusivity for ACTONEL in Western European markets and (iv) the growth of our promoted products as compared to the prior year. In addition our 2011 guidance accounts for revenues expected from the launch of ATELVIA and LO LOESTRIN FE in January 2011. The guidance does not ac
|SOURCE Warner Chilcott plc|
Copyright©2010 PR Newswire.
All rights reserved